News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
74,439 Results
Type
Article (2044)
Company Profile (1)
Press Release (72394)
Section
Business (23250)
Career Advice (10)
Deals (4847)
Drug Development (9593)
FDA (2142)
Job Trends (1121)
News (40795)
Policy (3897)
Tag
Academia (105)
Africa (80)
Alliances (8270)
ALS (2)
Alzheimer's disease (113)
Approvals (2142)
Artificial intelligence (2)
Asia (21137)
Australia (2433)
Bankruptcy (8)
Best Places to Work (885)
Biosimilars (5)
Biotechnology (3)
Breast cancer (3)
C2C Services and Suppliers (6783)
California (130)
Canada (114)
Cancer (40)
Career advice (10)
Cell therapy (2)
China (35)
Clinical research (8004)
Collaboration (13)
Connecticut (5)
COVID-19 (209)
Data (29)
Delaware (5)
Diabetes (8)
Diagnostics (700)
Drug discovery (2)
Earnings (8836)
Europe (13713)
Events (7581)
Executive appointments (9)
FDA (2170)
Florida (9)
Funding (9)
Gene editing (2)
Gene therapy (2)
GLP-1 (47)
Government (260)
Healthcare (1240)
Hotbed/Location (34393)
Illinois (6)
Indiana (6)
Infectious disease (209)
Inflammatory bowel disease (11)
IPO (1811)
Japan (6)
Job creations (243)
Job search strategy (10)
Kansas (5)
Layoffs (5)
Legal (951)
Liver cancer (14)
Lung cancer (8)
Maine (4)
Maryland (42)
MASH (3)
Massachusetts (103)
Medical device (1240)
Medtech (1241)
Mergers & acquisitions (3045)
Metabolic disorders (18)
Michigan (3)
Minnesota (19)
Neuroscience (122)
New Jersey (40)
New York (59)
NextGen Class of 2024 (248)
Non-profit (72)
North Carolina (41)
Northern California (77)
Obesity (5)
Ohio (3)
Parkinson's disease (4)
Patents (7)
Pennsylvania (20)
People (5008)
Phase I (2051)
Phase II (3254)
Phase III (3215)
Pipeline (18)
Postmarket research (339)
Preclinical (697)
Rare diseases (8)
Real estate (602)
Regulatory (2778)
Reports (6)
Research institute (108)
Series A (3)
South America (112)
Southern California (41)
Startups (425)
Texas (7)
United States (521)
Vaccines (13)
Venture capitalists (2)
Virginia (3)
Weight loss (3)
Date
Last 7 days (56)
Last 30 days (228)
Last 365 days (4238)
2024 (2830)
2023 (4545)
2022 (7805)
2021 (7127)
2020 (6534)
2019 (4285)
2018 (3317)
2017 (3897)
2016 (3442)
2015 (4330)
2014 (3235)
2013 (2717)
2012 (2876)
2011 (3019)
2010 (2781)
74,439 Results for "f2g ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim
F2G Ltd. and Shionogi & Co., Ltd., announced full results from the pivotal Phase 2b open-label study of olorofim in patients with proven invasive fungal infections or probable pulmonary invasive aspergillosis and limited or no treatment options.
October 21, 2023
·
10 min read
F2G to Present at Biotech Showcase™ 2023
F2G Ltd. today announced that the Company’s chief executive officer, Francesco Lavino will provide a corporate overview at Biotech Showcase™ 2023 taking place in San Francisco, California, from January 9-11, 2023.
January 5, 2023
·
4 min read
F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for The Treatment of Invasive Fungal Infections; Plans Resubmission With Additional Data and Analyses
F2G Ltd. today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for olorofim, an investigational antifungal, for the treatment of invasive fungal infections in patients who have limited or no treatment options.
June 19, 2023
·
5 min read
Business
Mid-Atlantic BioTherapeutics, Inc. and SMITM Capital Markets Ltd enter into a significant financing agreement
SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.
June 19, 2024
·
4 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022
F2G Ltd today announced that it will present new clinical data in three oral presentations and two poster presentations at IDWeek 2022, to be held in Washington, D.C. from October 19-23, 2022.
October 13, 2022
·
4 min read
Deals
Specac, Ltd Acquires Harrick Scientific
Specac, Ltd announced today the acquisition of Harrick Scientific, Inc.
April 2, 2024
·
3 min read
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems.
June 12, 2024
·
5 min read
Bioretec Ltd’s business review January-March 2024: Controlled launch in the U.S. progresses
This announcement summarizes Bioretec Ltd’s business review for January-March 2024.
May 16, 2024
·
6 min read
BioCapital
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.
June 6, 2024
·
3 min read
1 of 7,444
Next